ACM
AKRO

Atika Capital Management’s Akero Therapeutics AKRO Stock Holding History

Atika Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-79,935
Closed -$1.87M – 92
2023
Q4 		$1.87M Buy
+79,935
New +$1.58M 0.25% 69

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Atika Capital Management's AKRO Position: Q1 2024 in Review

Atika Capital Management sold out of Akero Therapeutics (AKRO) in Q1 2024, closing a stake of 79,935 shares — an estimated $1.87M sold.

Atika Capital Management first reported a position in AKRO in Q4 2023 and held it in 1 quarter. The position peaked at $1.87M in Q4 2023. 173 funds tracked by Wall St. Rank hold AKRO as of Q1 2024.

  • Atika Capital Management reported no remaining Akero Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Atika Capital Management sold 79,935 Akero Therapeutics shares in Q1 2024, an estimated $1.87M.
  • Atika Capital Management first reported a position in Akero Therapeutics in Q4 2023 and held it in 1 quarter.
  • Atika Capital Management's Akero Therapeutics position peaked at $1.87M in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2024.

Based on Atika Capital Management's 13F filing for Q1 2024, filed 14 May 2024.